New One-Year Data Reinforcing the Robust and Sustained Efficacy of EMPAVELI® (pegcetacoplan) in C3G and Primary IC-MPGN to be Presented at ASN Kidney Week

Significant proteinuria reduction maintained at one year, regardless of immunosuppressant use or baseline proteinuria levels Complete proteinuria ...

Apellis Pharmaceuticals, Inc.: New One-Year Data Reinforcing the Robust and Sustained Efficacy of EMPAVELI (pegcetacoplan) in C3G and Primary IC-MPGN to be Presented at ASN ...

Significant proteinuria reduction maintained at one year, regardless of immunosuppressant use or baseline proteinuria levels Complete proteinuria remission (UPCR =0.5 g/g) achieved in one-third of pat ...
Neurology Advisor

FDA Clears Blood Test for Early Detection of Amyloid Pathology

The FDA has cleared the Elecsys pTau181 test as an aid in early detection of amyloid pathology in the primary care setting for adults aged 55 years and older presenting with signs, symptoms or ...